Skip to main content

Day: August 26, 2024

Construction of a new building nearby Vilnius Akropolis is completed – it became home for the expanded and revamped Sportland store  

Written by Customer Service on . Posted in Public Companies.

Akropolis Vilnius SportlandAkropolis Vilnius SportlandA new commercial building of 480 sq. m has been constructed nearby Vilnius Akropolis. It houses Sportland – the expanded and modernised store offering sports and athleisure wear fashion brands. The previous premises of the shop have been expanded by connecting them to the new building, which has led to the increase of the store area to over 2,000 sq. m, making the store the biggest and most modern Sportland store in Lithuania. “We keep investing into the upgrade of the shopping and entertainment centres Akropolis, with focus on attracting new brands customers like, opening new and revamped stores and points of service. We are delighted that the increased area of the shopping and entertainment centre enabled choosing namely Akropolis as the place for the largest and most modern...

Continue reading

Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases

Written by Customer Service on . Posted in Public Companies.

20 abstracts, including 4 oral presentations, offer new treatment insights for chronic obstructive pulmonary disease (COPD), asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) Data from landmark Phase 3 trials for Dupixent in COPD reinforce exacerbation reduction and improvement in lung function compared to placebo, and provide new assessments on health-related quality of life across patient subgroups Additional presentations spotlight a novel asthma imaging study showing the early impact of Dupixent on clinical remission, airway remodeling and mucus plugging starting at 4 weeks, as well as data from investigational therapy itepekimab in former smokers with COPD TARRYTOWN, N.Y., Aug. 26, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced 20 abstracts across Dupixent® (dupilumab) and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.